Novartis AG
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
- Conditions
- HYPERTENSION
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 403
- Registration Number
- NCT00170976
- Locations
- π©πͺ
Sites in germany, Multiple Locations, Germany
π¨πNovartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 936
- Registration Number
- NCT00171002
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00171418
- Locations
- πΊπΈ
The Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
πΊπΈDrug Research Services, Inc, Metairie, Louisiana, United States
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00171483
- Locations
- πΊπΈ
Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States
πΊπΈDepartment of Internal Medicine - Wake Forest University School of Medicine, Winston Salem, North Carolina, United States
πΊπΈMiami Research Associates, Miami, Florida, United States
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 445
- Registration Number
- NCT00171145
- Locations
- πΊπΈ
Novartis, East Hanover, New Jersey, United States
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00170768
- Locations
- πΊπΈ
Washington Neuropsychological Institute LLC Georgetown, Washington, District of Columbia, United States
Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure
- Conditions
- Diastolic Dysfunction, Symptomatic Heart Failure
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00171106
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
- Conditions
- Hypothalamic Obesity
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00171613
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1018
- Registration Number
- NCT00170963
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
Fluvastatin in the Therapy of Acute Coronary Syndrome
- Conditions
- Coronary DiseaseMyocardial Infarction
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-07-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1000
- Registration Number
- NCT00171275
- Locations
- π¨πΏ
Novartis, Praha, Czech Republic